All Stories

  1. Bullying experiences of youth with neuromuscular disorders and their well-being: A survey study
  2. The Role of Mesenchymal Stromal Cells in the Treatment of Bronchopulmonary Dysplasia: A Multi‐Prong Approach for a Heterogeneous Disease
  3. NIPPV vs CPAP: Lessons from meta-analyses
  4. Cell-based therapies in preclinical models of necrotizing enterocolitis: a systematic review and meta-analysis
  5. Liver SMN restoration rescues the Smn mouse model of spinal muscular atrophy
  6. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation
  7. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants
  8. Congenital dyserythropoietic anemia type IV in the genetic era: A rare neonatal case report of rapid identification with a review of the literature
  9. Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
  10. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy
  11. Survival motor neuron protein deficiency alters microglia reactivity
  12. Resident Match During the COVID Pandemic: How Have Neurology Programs Adapted? – A Survey
  13. Central and peripheral delivery of AAV9-SMN target different pathomechanisms in a mouse model of spinal muscular atrophy
  14. Metabolic Dysfunction in Spinal Muscular Atrophy
  15. SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease
  16. Weakness is more prominent in males in a new mild mouse model of spinal muscular atrophy
  17. A mouse model for spinal muscular atrophy provides insights into non-alcoholic fatty liver disease pathogenesis
  18. Blood Flow to the Spleen is Altered in a Mouse Model of Spinal Muscular Atrophy
  19. Low fat diets increase survival of a mouse model of spinal muscular atrophy
  20. Impaired kidney structure and function in spinal muscular atrophy
  21. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy
  22. P.068 Abnormal fatty acid metabolism is a feature of spinal muscular atrophy
  23. Into the unknown
  24. SMA CLINICAL DATA, OUTCOME MEASURES AND REGISTRIES
  25. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice
  26. Abnormal fatty acid metabolism is a feature of spinal muscular atrophy
  27. New insights into SMA pathogenesis: immune dysfunction and neuroinflammation
  28. The glucocorticoid-KLF15-BCAA pathway as a novel therapeutic target for spinal muscular atrophy
  29. The role of the TWEAK/Fn14 pathway in muscle pathology in SMA
  30. Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice
  31. Oligodendrocyte development and CNS myelination are unaffected in a mouse model of severe spinal muscular atrophy
  32. Contributions of Different Cell Types to Spinal Muscular Atrophy Pathogenesis
  33. Differential induction of muscle atrophy pathways in two mouse models of spinal muscular atrophy
  34. Acute Stroke Research: Being Part of a Game-Changer with Dr. Dar Dowlatshahi, Scientific Director of the Ottawa Stroke Program
  35. Defects in muscle maturation contribute to spinal muscular atrophy.